CANF
Income statement / Annual
Last year (2024), Can-Fite BioPharma Ltd.'s total revenue was $674.00 K,
a decrease of 9.29% from the previous year.
In 2024, Can-Fite BioPharma Ltd.'s net income was -$7.88 M.
See Can-Fite BioPharma Ltd.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$674.00 K |
$743.00 K |
$810.00 K |
$853.00 K |
$763.00 K |
$2.03 M |
$3.82 M |
$844.75 K |
$169.50 K |
$164.72 K |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$674.00 K
|
$743.00 K
|
$810.00 K
|
$853.00 K
|
$763.00 K
|
$2.03 M
|
$3.82 M
|
$844.75 K
|
$169.50 K
|
$164.72 K
|
| Gross Profit Ratio |
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
| Research and Development Expenses |
$5.76 M
|
$5.98 M
|
$7.76 M
|
$9.85 M
|
$11.95 M
|
$10.98 M
|
$6.08 M
|
$5.27 M
|
$6.08 M
|
$3.86 M
|
| General & Administrative Expenses |
$3.05 M
|
$2.96 M
|
$3.14 M
|
$3.85 M
|
$2.95 M
|
$3.06 M
|
$3.16 M
|
$2.92 M
|
$2.70 M
|
$2.70 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$31.07 K
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$3.05 M
|
$2.96 M
|
$3.14 M
|
$3.85 M
|
$2.95 M
|
$3.06 M
|
$3.16 M
|
$2.95 M
|
$2.70 M
|
$2.70 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$109.00 K
|
$31.07 K
|
$28.86 K
|
$24.08 K
|
| Operating Expenses |
$8.80 M
|
$8.94 M
|
$10.91 M
|
$13.70 M
|
$14.90 M
|
$14.04 M
|
$9.23 M
|
$8.22 M
|
$8.80 M
|
$6.58 M
|
| Cost And Expenses |
$8.80 M
|
$8.94 M
|
$10.91 M
|
$13.70 M
|
$14.90 M
|
$14.04 M
|
$9.23 M
|
$8.22 M
|
$8.80 M
|
$6.58 M
|
| Interest Income |
$291.00 K
|
$506.00 K
|
$222.00 K
|
$24.00 K
|
$44.00 K
|
$72.00 K
|
$51.00 K
|
$2.99 M
|
$88.91 K
|
$1.92 M
|
| Interest Expense |
$14.00 K
|
$14.00 K
|
$77.00 K
|
$18.00 K
|
$363.00 K
|
$427.00 K
|
$1.20 M
|
$1.10 M
|
$27.30 K
|
$564.34 K
|
| Depreciation & Amortization |
$7.00 K
|
$15.00 K
|
$14.00 K
|
$14.00 K
|
$12.00 K
|
$14.00 K
|
$14.00 K
|
$19.85 K
|
$18.46 K
|
$16.39 K
|
| EBITDA |
-$8.12 M |
-$8.18 M |
-$10.08 M |
-$12.83 M |
-$14.13 M |
-$11.99 M |
-$6.13 M |
-$7.17 M |
-$8.68 M |
-$6.40 M |
| EBITDA Ratio |
-12.05
|
-11.01
|
-12.45
|
-15.04
|
-18.52
|
-5.9
|
-1.6
|
-8.48
|
-51.19
|
-38.85
|
| Operating Income Ratio |
-12.06
|
-11.03
|
-12.46
|
-15.06
|
-18.53
|
-5.91
|
-1.42
|
-8.73
|
-50.94
|
-38.95
|
| Total Other Income/Expenses Net |
$250.00 K
|
$561.00 K
|
-$77.00 K
|
$227.00 K
|
-$304.00 K
|
-$618.00 K
|
-$1.15 M
|
$781.00 K
|
$269.86 K
|
$1.35 M
|
| Income Before Tax |
-$7.88 M
|
-$7.63 M
|
-$10.17 M
|
-$12.62 M
|
-$14.44 M
|
-$12.63 M
|
-$6.57 M
|
-$4.95 M
|
-$6.99 M
|
-$5.06 M
|
| Income Before Tax Ratio |
-11.69
|
-10.27
|
-12.56
|
-14.79
|
-18.93
|
-6.21
|
-1.72
|
-5.86
|
-41.25
|
-30.72
|
| Income Tax Expense |
$0.00
|
$0.00
|
$360.00 K
|
-$20.00 K
|
$363.00 K
|
$427.00 K
|
$4.00 K
|
$29.92 K
|
$29.12 K
|
$4.35 K
|
| Net Income |
-$7.88 M
|
-$7.63 M
|
-$10.53 M
|
-$12.60 M
|
-$14.81 M
|
-$13.05 M
|
-$6.57 M
|
-$4.97 M
|
-$6.90 M
|
-$4.80 M
|
| Net Income Ratio |
-11.69
|
-10.27
|
-13
|
-14.77
|
-19.4
|
-6.42
|
-1.72
|
-5.88
|
-40.69
|
-29.12
|
| EPS |
-1.08 |
-1.8 |
-3.75 |
-8.25 |
-12.69 |
-45 |
-51 |
-57 |
-90 |
-81 |
| EPS Diluted |
-1.08 |
-1.8 |
-3.75 |
-8.25 |
-12.69 |
-45 |
-51 |
-57 |
-90 |
-81 |
| Weighted Average Shares Out |
$7.25 M
|
$4.26 M
|
$2.72 M
|
$1.53 M
|
$1.14 M
|
$286.37 K
|
$129.67 K
|
$108.42 K
|
$92.31 K
|
$76.51 K
|
| Weighted Average Shares Out Diluted |
$7.25 M
|
$4.26 M
|
$2.72 M
|
$1.84 M
|
$1.19 M
|
$286.37 K
|
$129.67 K
|
$108.42 K
|
$92.31 K
|
$76.51 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
